Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
codeine phosphate hemihydrate,paracetamol
Alphapharm Pty Ltd
Registered
CODAPANE FORTE _Paracetamol and codeine phosphate hemihydrate_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Codapane Forte. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Codapane Forte against the benefits this medicine is expected to have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT CODAPANE FORTE IS USED FOR Codapane Forte is used to relieve moderate to severe pain, and fever. Codapane Forte contains paracetamol and codeine. These ingredients work together to stop the pain messages from reaching the brain. Paracetamol also acts in the brain to reduce fever. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY CODAPANE FORTE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed Codapane Forte for another reason. This medicine may be addictive after repeated administration. Codapane Forte is not recommended for children under 12 years of age. This medicine is available only with a doctor's prescription. BEFORE YOU TAKE CODAPANE FORTE _WHEN YOU MUST NOT TAKE IT_ DO NOT TAKE CODAPANE FORTE IF YOU HAVE AN ALLERGY TO: • any medicine containing paracetamol or codeine • any of the ingredients listed at the end of this leaflet • any other similar medicines, such as morphine and oxycodone. • Aspirin or any other NSAID medicine. Some of the symptoms of an allergic reaction may include: • shortness of breath • wheezing or difficulty breathing • swelling of the face, lips, tongue or other parts of the body • rash, itching or hives on the skin. DO NOT TAKE CODAPANE FORTE IF YOU HAVE: • breathing difficulties, such as asthma, bronchitis or emphysema • Glucose-6-phosphate dehydrogenase deficiency (an enzyme deficiency) • Ultra-rapid metaboliser of CYP2D6 • diarrhoe Lugege kogu dokumenti
PRODUCT INFORMATION CODAPANE FORTE _Paracetamol and codeine phosphate hemihydrate _ NAME OF THE MEDICINE Active ingredient : Paracetamol Chemical name : N-(4-Hydroxyphenyl)acetamide Structural formula : Molecular formula : C 8 H 9 NO 2 Molecular weight : 151.17 CAS Registry no. : 103-90-2 Active ingredient : Codeine phosphate hemihydrate Chemical name : 7,8-Didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate hemihydrate Structural formula : Molecular formula : C 18 H 24 NO 7 P, ½H 2 O Molecular weight : 406.37 CAS Registry no. : 41444-62-6 CODAPANE FORTE – Product Information 2 DESCRIPTION Paracetamol is a white crystalline powder, sparingly soluble in water, freely soluble in alcohol, very slightly soluble in ether and in methylene chloride. Codeine phosphate hemihydrate appears as white, crystalline powder or small colourless crystals, freely soluble in water, slightly soluble in alcohol, practically insoluble in ether. Codapane Forte tablets contain 500 mg of paracetamol (present as “Compap L”) and 30 mg of codeine phosphate hemihydrate as the active ingredients. Codapane Forte tablets also contain the following inactive ingredients: crospovidone, colloidal anhydrous silica, sodium lauryl sulfate, stearic acid and magnesium stearate. PHARMACOLOGY Analgesic and antipyretic: There is evidence to suggest that a combination of paracetamol with codeine is superior in analgesic action to either drug administered alone. PHARMACOKINETICS PARACETAMOL ABSORPTION After oral administration, paracetamol is absorbed rapidly and completely from the small intestine; peak plasma levels occur 15 to 75 minutes after administration. These results are not significantly different to those of Panadeine ® Forte. Food intake delays paracetamol absorption. DISTRIBUTION Paracetamol is uniformly distributed throughout most body fluids; the apparent volume of distribution is 1 to 1.2 L/kg. Paracetamol can cross the placenta and is excreted in milk. Plasma protein binding is negligible at usual therapeutic concentra Lugege kogu dokumenti